Advertisement

Immunologic Research

, Volume 66, Issue 3, pp 340–347 | Cite as

Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests

  • Maria Infantino
  • M. Manfredi
  • M. Merone
  • V. Grossi
  • M. Benucci
  • F. Li Gobbi
  • F. Bandinelli
  • A. Damiani
  • P. Soda
Original Article
  • 106 Downloads

Abstract

Anti-dsDNA antibodies are a heterogeneous group of antibodies, quite specific for SLE. Their variability is related to the assay used, the immunoglobulin class secondary antibody, and the dsDNA source. The standardization of measuring anti-dsDNA antibodies is still poor and different methods yield different results. Several novel technologies were developed during the last decades that represent viable alternatives to the traditional methods such as the chemiluminescent immunoassay (CIA) and multiplex flow immunoassay (MFI). Additionally, positive results for anti-dsDNA antibodies can be detected in patients with inflammatory arthritis (IA) treated with different biologics reducing its clinical specificity for SLE. Anti-dsDNA antibody levels were evaluated in 246 patient samples: 70 SLE and 176 disease control (including 96 IA during treatment with different biologics), using three enzyme immunoassays (indirect enzyme immunoassay, Bio-Rad Laboratories; chemiluminescent immunoassay, Inova Diagnostics; multiplex flow immunoassay, Bio-Rad Laboratories) and three Crithidia luciliae immunofluorescence tests (CLIFT) (Euroimmun AG, Bio-Rad Laboratories, INOVA Diagnostics). Diagnostic performances were assessed both including and excluding the IA patients. Agreements, measured by the Cohen’s Kappa between all methods, ranged from moderate to substantial (0.47–0.68). The clinical sensitivities for the anti-dsDNA antibody tests varied from 5.7% by CLIFT A up to 33.3% provided by EIA while the clinical specificities varied from 89.8% by MFI to 98.9% provided by CLIFT B and C. Newer technologies, such as MFI and CIA, showed great potential as a diagnostic application. Significant variations among anti-dsDNA antibody assays were observed confirming the lack of standardization.

Keywords

Anti-dsDNA antibodies Standardization Intermethods variability SLE classification criteria 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010;10:3–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res. 2013;55:10–21.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMedGoogle Scholar
  5. 5.
    Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Field AK, Davies ME, Tytell AA. Determination of antibodies to double–stranded RNA by enzyme-linked immunosorbent assay (ELISA). Proc Soc Exp Biol Med. 1980;164:524–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Eilat D, Hochberg M, Pumphrey J, Rudikoff S. Monoclonal antibodies to DNA and RNA from NZB/NZW F1 mice: antigenic specificities and NH2 terminal amino acid sequences. J Immunol. 1984;133:489–94.PubMedGoogle Scholar
  8. 8.
    Infantino M, Meacci F, Bentow C, Martis P, Benucci M, Afeltra A, et al. Clinical comparison of QUANTA Flash dsDNA chemiluminescent immunoassay with four current assays for the detection of anti-dsDNA autoantibodies. J Immunol Res. 2015;2015:902821.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Almeida González D, Roces Varela A, Marcelino Rodríguez I, González Vera A, Delgado Sánchez M, Aznar Esquivel A, et al. Anti-dsDNA antibodies in systemic lupus erythematosus: a combination of two quantitative methods and the ANA pattern is the most efficient strategy of detection. J Immunol Methods. 2015;427:30–5.CrossRefPubMedGoogle Scholar
  10. 10.
    de Leeuw K, Bungener L, Roozendaal C, Bootsma H, Stegeman CA. Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. Lupus. 2013;22:1169–73.CrossRefGoogle Scholar
  11. 11.
    Hillebrand JJ, Bernelot Moens HJ, Mulder AH. Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. Lupus. 2013;22:1169–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G, et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci. 2005;1050:380–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Shovman O, Gilburd B, Zandman-Goddard G, Yehiely A, Langevitz P, Shoenfeld Y. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity. 2005;38:105–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Mahler M, Radice A, Yang W, Bentow C, Seaman A, Bianchi L, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012;413:719–26.CrossRefPubMedGoogle Scholar
  15. 15.
    Infantino M, Bentow C, Seaman A, Benucci M, Atzeni F, Sarzi-Puttini P, et al. Highlights on novel technologies for the detection of antibodies to Ro60, Ro52, and SS-B. Clin Dev Immunol. 2013;2013:978202.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Antico A, Platzgummer S, Bassetti D, Bizzaro N, Tozzoli R, Villalta D. Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test. Lupus. 2010;19:906–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Pérez D, Gilburd B, Cabrera-Marante Ó, Martínez-Flores JA, Serrano M, Naranjo L, et al. Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies. Clin Chem Lab Med. 2017;Google Scholar
  18. 18.
    Ghirardello A, Villalta D, Morozzi G, Afeltra A, Galeazzi M, Gerli R, et al. Evaluation of current methods for the measurement of serum anti double-stranded DNA antibodies. Ann N Y Acad Sci. 2007;1109:401–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53:424–32.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rouquette AM, Desgruelles C. Detection of antibodies to dsDNA: an overview of laboratory assays. Lupus. 2006;15:403–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey’s end? Rheumatology. 2007;46:10526.Google Scholar
  22. 22.
    Fiegel F, Buhl A, Jaekel HP, Werle E, Schmolke M, Ollert M, et al. Autoantibodies to double-stranded DNA intermethod comparison between four commercial immunoassays and a research biosensor-based device. Lupus. 2010;19:95764.CrossRefGoogle Scholar
  23. 23.
    Smeenk R, van der Lelij G, Aarden L. Measurement of low avidity anti-dsDNA by the Crithidia luciliae test and the PEG assay. Clin Exp Immunol. 1982;49:603–10.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17–23.CrossRefPubMedGoogle Scholar
  25. 25.
    Ghirardello A, Villalta D, Morozzi G, Afeltra A, Galeazzi M, Gerli R, et al. Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol. 2011;29:50–6.PubMedGoogle Scholar
  26. 26.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005;52:2192–201.CrossRefPubMedGoogle Scholar
  27. 27.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383–90.CrossRefPubMedGoogle Scholar
  28. 28.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Caramaschi P, Bambara LM, Pieropan S, Tinazzi I, Volpe A, Biasi D. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine. 2009;76:333–42.CrossRefPubMedGoogle Scholar
  30. 30.
    Infantino M, Grossi V, Benucci M, Li Gobbi F, Damiani A, Manfredi M. The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests. Lupus. 2017;1:961203317709344.Google Scholar
  31. 31.
    Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46:357–65.CrossRefPubMedGoogle Scholar
  32. 32.
    Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Moder KG, Wener MH, Weisman MH, Ishimori ML, Wallace DJ, Buckeridge DL, et al. Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation. J Rheumatol. 2007;34(5):978–86.PubMedGoogle Scholar
  34. 34.
    Mahler M, Bentow C, Serra J, Fritzler MJ. Detection of autoantibodies using chemiluminescence technologies. Immunopharmacol Immunotoxicol. 2016;38:14–20.CrossRefPubMedGoogle Scholar
  35. 35.
    Bentow C, Lakos G, Martis P, Wahl E, Garcia M, Viñas O, et al. International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. Lupus. 2016;25:864–72.CrossRefPubMedGoogle Scholar
  36. 36.
    Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol. 2013;9:687–94.CrossRefPubMedGoogle Scholar
  37. 37.
    Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:315179.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Mahler M, Dervieux T. Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies. Ann Rheum Dis. 2014;73:e36.CrossRefPubMedGoogle Scholar
  39. 39.
    Enocsson H, Sjöwall C, Wirestam L, Dahle C, Kastbom A, Rönnelid J, et al. Four anti-dsDNA antibody assays in relation to systemic lupus erythematosus disease specificity and activity. J Rheumatol. 2015;42:817–25.CrossRefPubMedGoogle Scholar
  40. 40.
    Biesen R, Dähnrich C, Rosemann A, Barkhudarova F, Rose T, Jakob O, et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:R26.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Launay D, Schmidt J, Lepers S, Mirault T, Lambert M, Kyndt X, et al. Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. Clin Chim Acta. 2010;411:959–64.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Maria Infantino
    • 1
  • M. Manfredi
    • 1
  • M. Merone
    • 2
  • V. Grossi
    • 1
  • M. Benucci
    • 3
  • F. Li Gobbi
    • 3
  • F. Bandinelli
    • 3
  • A. Damiani
    • 3
  • P. Soda
    • 2
  1. 1.Immunology and Allergology Laboratory UnitS. Giovanni di Dio HospitalFlorenceItaly
  2. 2.Computer Systems & Bioinformatics Laboratory, Department of EngineeringUniversity Campus Bio-MedicoRomeItaly
  3. 3.Rheumatology UnitS. Giovanni di Dio HospitalFlorenceItaly

Personalised recommendations